Development of a SFTSV DNA vaccine that confers complete protection against lethal infection in ferrets

Cited 0 time in webofscience Cited 0 time in scopus
  • Hit : 83
  • Download : 3
Although the incidence of severe fever with thrombocytopenia syndrome virus (SFTSV) infection has increased from its discovery with a mortality rate of 10-20%, no effective vaccines are currently available. Here we describe the development of a SFTSV DNA vaccine, its immunogenicity, and its protective efficacy. Vaccine candidates induce both a neutralizing antibody response and multifunctional SFTSV-specific T cell response in mice and ferrets. When the vaccine efficacy is investigated in aged-ferrets that recapitulate fatal clinical symptoms, vaccinated ferrets are completely protected from lethal SFTSV challenge without developing any clinical signs. A serum transfer study reveals that anti-envelope antibodies play an important role in protective immunity. Our results suggest that Gn/Gc may be the most effective antigens for inducing protective immunity and non-envelope-specific T cell responses also can contribute to protection against SFTSV infection. This study provides important insights into the development of an effective vaccine, as well as corresponding immune parameters, to control SFTSV infection.
Publisher
NATURE PUBLISHING GROUP
Issue Date
2019-08
Language
English
Article Type
Article
Citation

NATURE COMMUNICATIONS, v.10, pp.3836

ISSN
2041-1723
DOI
10.1038/s41467-019-11815-4
URI
http://hdl.handle.net/10203/267430
Appears in Collection
MSE-Journal Papers(저널논문)
Files in This Item
s41467-019-11815-4.pdf(1.99 MB)Download

qr_code

  • mendeley

    citeulike


rss_1.0 rss_2.0 atom_1.0